Röchling Medical has ceremoniously marked the expansion of its site in Neuhaus am Rennweg, Germany.

With the fabrication of a new production building to scale up existing production capacity, Röchling is laying the groundwork for the future growth of its medical division.

With Vice-chairman of Röchling Group’s advisory board Dr Carl Peter Thürmel in attendance, the new building was ceremoniously opened by Röchling Group and Medical division CEO professor Hanns-Peter Knaebel, who transferred the building to BU director medical Europe Joachim Lehmann and to Managing director BU medical Europe Alexander Stauch.

The Röchling Group is investing €35m in its Neuhaus am Rennweg site, creating around 70 new jobs for specialists and managerial staff in the process. The production capacities of Röchling Medical Neuhaus are being increased significantly and the market position of the specialist in manufacturing primary packaging for the pharmaceutical and diagnostics industries is being strengthened considerably.

Signs point to growth

The Röchling Group launched the medical division in 2016 to support its industrial and automotive divisions, as well as setting the scene for a clear strategic focus on developing and manufacturing high-quality plastic products for pharmaceutical, diagnostics, surgical and life sciences applications.

Röchling Medical develops innovative solutions across these sectors, strengthening its market position worldwide. Through intensive marketing efforts, this has spurred Röchling Medical on to win major projects necessitating the expansion of production capacity in the area of co-extrusion blow moulding.

At its site in Neuhaus am Rennweg, a new production building has been built that houses the manufacture of primary packaging for pharmaceutical products under ultra-modern Class good manufacturing practice (GMP) C (approximately 1,100m²) and Class GMP D (approximately 500m²) cleanroom conditions.